At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 245 enrolled
Drug / intervention
Ramucirumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Ramucirumab and Paclitaxel for Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Completed, enrolled 245 participants across 52 sites in 11 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Czechia, Germany, Greece, Italy, Spain, Sweden, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartOct 2015
Primary CompletionOct 2017
Study CompletionDec 2018
TodayJul 2026
First PostedAug 3, 2015
Enrollment StartOct 12, 2015
Primary CompletionOct 27, 2017
Study CompletionDec 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.9 years ago
Interventions
Ramucirumabdrug
Administered IV
Paclitaxeldrug
Administered IV